ZFP36L1 and familial hypercholesterolemia: As the LDLR has previously been demonstrated to be important for hypercholesterolemia-associated breast cancer growth in preclinical models, future studies should explore if targeting MAPK, RSK signaling or ZFP36L1 activity in TNBC provides an additive benefit in the setting of hypercholesterolemia.